Massachusetts Enacts New Biosimilars Substitution Law

by Foley Hoag LLP

On June 23, 2014, Governor Deval Patrick signed into law House Bill 3734, “An Act Relative to the Substitution of Interchangeable Biosimilars” (now Chapter 143 of the Acts of 2014). The new Act authorizes pharmacists to substitute so-called “interchangeable” biological products when filling a prescription for brand biological products, so long as the substitution complies with five requirements. These five requirements are:

  1. Pharmacists may only substitute biosimilars that the Food and Drug Administration (FDA) has determined to be “interchangeable” with the prescribed product;
  2. Prescribing doctors retain “dispense as written” authority;
  3. Pharmacists must notify prescribing doctors of biosimilars substitutions
  4. Pharmacists must notify patients of biosimilars substitutions; and
  5. Pharmacists must retain records of biosimilars substitutions for a year.

While no FDA-approved biosimilar products are yet on the market, Massachusetts is in the vanguard of planning ahead for the arrival of interchangeable biological products. With the enactment of the Act, Massachusetts becomes only the seventh state to pass such legislation.

Biosimilar and Interchangeable Products

Biosimilars are biologic drugs that are very similar to — but not identical to — a “reference” (often branded) biological product. In 2010, Congress passed the “Biologics Price Competition and Innovation Act of 2009” (BPCIA), which authorizes a pathway for FDA approval of biological products that are interchangeable with the reference product.

Under BPCIA, the FDA can determine that a product is “interchangeable” with a reference product if (1) the biosimilar product is expected to produce the same clinical result as the reference product in any given patient, and (2) switching between the reference product and the biosimilar product does not increase the safety risk or reduce effectiveness.

In the four years since the enactment of BPCIA, FDA has not yet approved an interchangeable biosimilar. However, FDA officials have recently noted that the agency has met with numerous companies to discuss the submission of biosimilar applications, and several companies have indicated publicly that they expect to submit biosimilar applications to the FDA in the near future.

The Massachusetts Biosimilars Act

The new Massachusetts Act expands pharmacists’ authority, allowing them to now substitute interchangeable biosimilars for prescribed branded biologics in addition to exercising their existing authority under G.L. c. 112 § 12D (“Section 12D”) to substitute generic drugs for prescribed branded drugs.

As noted above, the Act establishes five requirements that must be met in connection with the substitution of an interchangeable biosimilar. Certain of these requirements are similar to those currently in effect under Section 12D for the substitution of interchangeable generic drugs.

First, the pharmacist may only substitute products that have been determined by the FDA to be interchangeable with the biologic product named on the prescription. Second, if the prescribing practitioner instructs “dispense as written” on the prescription, then the pharmacist may not override the instruction and dispense an interchangeable biological product. Both of these requirements already apply to the substitution of generic drugs under Section 12D.

Third, the pharmacist must notify the prescribing practitioner of the substitution within a reasonable time by either a notation in the patient’s electronic health record (or, if an electronic record is not used, by fax, paper record, or electronic transmission). Fourth, the pharmacist must notify the patient or his/her authorized representative of the substitution by fax, by electronic transmission, by notation in the record system, or by another means consistent with the patient notice procedures for the substitution of generic drugs under Section 12D. Finally, the Act requires pharmacists to retain a record of each interchangeable biosimilar substitution for a year — a requirement that is consistent with current state drug dispensing regulations.

The general expectation is that once interchangeable biological products arrive on the market, they will be used interchangeably with branded biological products. Since several of the requirements in the Act already exist in state laws governing the dispensing and substitution of generic drugs, they will likely already be familiar to pharmacists.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley Hoag LLP | Attorney Advertising

Written by:

Foley Hoag LLP

Foley Hoag LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.